What do I need to provide?

An antigen sequence or a 3D structure (PDB or AlphaFold). No confidential data is needed for the initial feasibility check. For lab validation, we will confirm together how the antigen is sourced.

How much does it cost?

Pricing depends on the package, the number of variants and the target. Send us your target and you will receive a tailored quote.

What happens if no candidate meets the success criteria?

On the Ready-to-use Antibodies package, if no candidate shows binding in ELISA or FACS and at least 50 mg/L yield in CHO, you do not pay. Ask us for the full conditions.

What if I don't have a 3D structure?

AIxplore® can use structural modeling based on the amino acid sequence of the target.

Which antibody formats can be generated?

VHH, Fab, scFv and full IgG sequences can be generated, with downstream reformatting possibilities including bispecific antibodies, ADCs and CAR-T constructs.

Can I start with sequences and request production later?

Yes. You can start with the Express Sequence Package and move to production and characterization later.

Who owns the AI-generated sequences?

After full service payment, the intellectual property of the AI-generated sequences belongs to the customer, with no additional royalties or milestone payments.

How is my target data handled?

Target structures and sequences are not re-entered into public databases or used to train third-party models.

AIxplore® · De novo antibody design services

AI antibody design, wet-lab validated in 3 weeks

Send us a target sequence or structure. Get up to 46 experimentally tested antibody candidates, with binding confirmed and production yield measured. Sequences are generated in 2–3 days.

✓

No Win, No Fee. At least one candidate guaranteed.

Binding in ELISA or FACS + minimum 50 mg/L yield in CHO.

VHH · Fab · scFv · IgG
100% IP-free, no royalties
No immunization needed

Discuss Your Target See Experimental Results

2–3 days Sequence generation

3 weeks Wet-lab validation

40+ criteria Integrated from initial design

Fully human Sequence

100% IP-free No royalties or milestone payments

De novo antibody design workflow

From target input to wet-lab validated antibodies

One integrated workflow combining rapid AI antibody design with experimental validation in our wet lab.

Day 0

Target Input

Start from an antigen sequence or a 3D structure (PDB or AlphaFold).

Input Antigen sequence or 3D structure

2–3 Days

AI Design

We design and select antibody candidates across 40+ criteria, including developability, manufacturability, solubility and aggregation, stability, immunogenicity and chemical liabilities.

Output Designed antibody sequences

3 Weeks

Wet-Lab Validation

Selected candidates are produced and experimentally evaluated by ELISA, affinity measurement by BLI, and production QC for yield, purity and integrity.

Output Experimentally validated antibodies

What this changes for researchers

Remove biological waiting steps from antibody discovery

AI design changes what needs to happen before you can start testing antibody candidates.

No antigen production for discovery

Start directly from the target sequence or structure. Antigen production is only needed later if required for wet-lab validation.

No immunization for discovery

No immunization or animal use is required for the discovery step.

Developability from day one

Key developability and manufacturability constraints are considered during initial design—not after binder identification.

When to Consider De Novo AI Design

Where de novo antibody design adds the most value

De novo AI design is particularly relevant when the target, desired binding site or experimental constraints make conventional antibody discovery more challenging.

01

Defined epitopes & functional sites

Design antibodies toward specific structural regions, such as functional epitopes, active sites or accessible pockets.
02

Membrane proteins & complex targets

Start from sequence or available 3D structural data when antigen production or purification is particularly challenging.
03

Toxic or poorly immunogenic targets

Generate candidates without animal immunization for toxic, highly conserved or poorly immunogenic targets.
04

Fc-fusion & tagged antigens

Focus design on the target region to help reduce unwanted recognition of Fc or other fusion tags.
05

Rescue after unsuccessful screening

Explore an alternative sequence and structural search space when previous screening produces few or no suitable hits.
06

Developability from day one

Consider 40+ criteria from the initial design, including developability, manufacturability, stability, solubility and immunogenicity.

Two ways to start

Choose how far you want us to go.

Need sequences for your own experimental workflow, or want us to take selected candidates through production and characterization? Both start from the same AIxplore® design workflow.

Option 1

Express Sequence Package

Delivery of ranked AI-designed antibody sequences.

2–3 days
Delivery

Ideal if you express & test in-house.

✓ Antigen analysis
✓ In silico generation
✓ Multi-parametric filtering
✓ Scoring on selected criteria to rank sequences
✓ Review by our bioinformaticians

Get AI-Designed Sequences

Option 2

Ready-to-use Antibodies Package

Delivery of purified & characterized antibodies.

3 weeks
Delivery

Ideal to receive already validated antibodies.

✓ Amino acid sequences of AI-generated variants
✓ Up to 46 recombinant variants, up to 1 mg each
✓ Production yields & QCs
✓ ELISA results
✓ KD determination by BLI for up to 10 best-performing variants in ELISA
✓ Detailed report
✓ Customer-owned IP after full service payment, with no extra royalties or milestone payments

Optional: Epitope & Paratope Mapping

Detailed report including top docking solutions (3D models),
predicted epitope and paratope residues with confidence levels,
main epitope/paratope regions, and transfer of the mapping-data
IP to the customer.

Get Ready-to-use Antibodies

Experimental evidence
Designed by AI. Tested in the lab.

Evaluate AIxplore® through measured experimental results.

Immuno-Oncology
✓ Wet-Lab Confirmed

PD-L1 · De Novo VHH Design

10–20 nM affinity without affinity maturation

46 VHH candidates designed and produced directly from the target structure.

24% Hit rate

11 / 46Confirmed binders

10–20 nM Lead KD

Full case report →

Cardiovascular & Hematology
✓ Multi-Epitope Validated

GPVI · De Novo Antibody Design

85% hit rate across three epitope strategies

Three published GPVI epitopes targeted in parallel using de novo antibody design.

85% Hit rate

39Confirmed ELISA binders

35 & 40 nM BLI · 2 VHHs

Full case report →

Discuss your target with our team

FAQ

Questions before starting?

Ready to test your target?

Tell us what you are working on and get a feasibility check from our bioinformatics team.

Reply within 1 business day
No sequence or structure needed to start
NDA available

? Not sure if your target is suitable?

Send us your target name, sequence, structure, or simply your project objective. Our team will assess the best starting point.

AI antibody design, wet-lab validated in 3 weeks